Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288073 · ClinicalTrials.gov registry record · Phase 2
TIL Therapy in cSCC and MCC
A Phase 2 study of Skin Cancer and Merkel Cell Carcinoma, sponsored by Karam Khaddour, MD, MS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07288073 is a Phase 2 study of Skin Cancer and Merkel Cell Carcinoma that is actively recruiting participants, run by Karam Khaddour, MD, MS. The registered enrollment target is 14 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07288073, a Phase 2 study of Skin Cancer and Merkel Cell Carcinoma, is actively recruiting participants, sponsored by Karam Khaddour, MD, MS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with Cutaneous squamous cell carcinoma (CSCC) or Merkel Cell Carcinoma (MCC) who were previously treated with immunotherapy. The names of the study interventions involved in this study are: * Tumor Infiltrating Lymphocytes (a type of cellular therapy) * Fludarabine and Cyclophosphamide (types of standard of care chemotherapy drugs) * Interleukin-2 (a type of recombinant, human glycoprotein)
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL LN-145
- BIOLOGICAL Interleukin-2
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2029-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07288073
The ClinicalTrials.gov registry entry for NCT07288073 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Karam Khaddour, MD, MS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Skin Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07288073 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07288073 about?
NCT07288073 is a clinical study titled "TIL Therapy in cSCC and MCC". The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with...
What is the current status of trial NCT07288073?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-02-10. Estimated completion is 2029-06-29.
What conditions does trial NCT07288073 study?
This clinical trial studies the following conditions: Skin Cancer, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT07288073?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), LN-145 (BIOLOGICAL), Interleukin-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07288073?
This trial is sponsored by Karam Khaddour, MD, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288073 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
COMPLETED · Phase 2
-
Study of Talabostat and Cisplatin in Advanced Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.